



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

EMA/635148/2017

European Medicines Agency decision

P/0298/2017

of 4 October 2017

on the granting of a product specific waiver for ibrutinib (Imbruvica), (EMEA-001397-PIP05-17) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Only the English text is authentic.



European Medicines Agency decision

P/0298/2017

of 4 October 2017

on the granting of a product specific waiver for ibrutinib (Imbruvica), (EMA-001397-PIP05-17) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004¹,

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency²,

Having regard to the application submitted by Janssen-Cilag International N.V. on 16 August 2017 under Article 13 of Regulation (EC) No 1901/2006,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 15 September 2017 in accordance with Article 13 of Regulation (EC) No 1901/2006,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

- (1) The Paediatric Committee has given an opinion on the granting of a product specific waiver.
- (2) It is therefore appropriate to adopt a decision granting a waiver.

Has adopted this decision:

Article 1

A waiver for ibrutinib (Imbruvica), film-coated tablet, oral use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 2

This decision is addressed to Janssen-Cilag International N.V., Turnhoutseweg 30, B-2340 - Beerse, Belgium.

Article 3

This decision covers all conditions, indications, pharmaceutical forms, routes of administration, as agreed in the decision P/0149/2013 issued on 3 July 2013.

¹ OJ L 378, 27.12.2006, p.1.

² OJ L 136, 30.4.2004, p. 1.



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

EMA/PDCO/543608/2017

London, 15 September 2017

Opinion of the Paediatric Committee on the granting of a product-specific waiver

EMA-001397-PIP05-17

Scope of the application

Active substance(s):

Ibrutinib

Invented name:

Imbruvica

Condition(s):

Treatment of mantle cell lymphoma

Authorised indication(s):

See Annex II

Pharmaceutical form(s):

Film-coated tablet

Route(s) of administration:

Oral use

Name/corporate name of the PIP applicant:

Janssen-Cilag International N.V.

Information about the authorised medicinal product:

See Annex II



Basis for opinion

Pursuant to Article 13 of Regulation (EC) No 1901/2006 as amended, Janssen-Cilag International N.V. submitted to the European Medicines Agency on 16 August 2017 an application for a product-specific waiver on the grounds set out in Article 11 of said Regulation for the above mentioned medicinal product.

The procedure started on 12 September 2017.

Opinion

1. The Paediatric Committee, having assessed the waiver application in accordance with Article 13 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:
 - to grant a product-specific waiver for all subsets of the paediatric population and the above mentioned condition(s) in accordance with Article 11(1)(b) of said Regulation, on the grounds that the disease or condition for which the specific medicinal product is intended occurs only in adult populations.

The Norwegian Paediatric Committee member agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The grounds for the granting of the waiver are set out in Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annexes and appendix.

Annex I

Grounds for the granting of the waiver

1. Waiver

1.1. Condition

Treatment of mantle cell lymphoma

The waiver applies to:

- the paediatric population from birth to less than 18 years of age;
- film-coated tablet, oral use;
- On the grounds that the disease or condition for which the specific medicinal product is intended does not occur in the specified paediatric subset(s).

Annex II

Information about the authorised medicinal product

Condition(s) and authorised indication(s):

1. Treatment of mantle cell lymphoma

Authorised indication(s):

- IMBRUVICA as a single agent is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma

2. Treatment of chronic lymphocytic leukaemia

Authorised indication(s):

- IMBRUVICA as a single agent is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL)
- IMBRUVICA as a single agent or in combination with bendamustine and rituximab (BR) is indicated for the treatment of adult patients with CLL who have received at least one prior therapy.

3. Treatment of lymphoplasmacytic lymphoma

Authorised indication(s):

- IMBRUVICA as a single agent is indicated for the treatment of adult patients with Waldenström's macroglobulinaemia (WM) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo-immunotherapy.

Authorised pharmaceutical form(s):

Capsule, hard

Authorised route(s) of administration:

Oral use